Core Viewpoint - The company reported a steady improvement in its operational performance for Q3 2025, with revenue and net profit showing slight year-on-year growth, while also addressing the increased health demands due to a flu outbreak by ensuring stable supply of essential medications and protective supplies [1]. Group 1: Financial Performance - For Q3 2025, the company achieved a revenue of 5.296 billion yuan, representing a year-on-year growth of 0.07%, and a net profit attributable to shareholders of 131 million yuan, reflecting a year-on-year increase of 2.6% [1]. - The company has a total of 15,492 stores across 18 provincial markets and over 150 cities, with 9,741 being direct-operated and 5,751 being franchised [1]. Group 2: Supply Chain and Product Strategy - In response to the surge in health demands, the company leveraged its nationwide supply chain and store network to ensure the availability of four key types of medications and protective supplies, with sufficient inventory and stable prices [1]. - Sales of the four key medication categories have seen a month-on-month increase since November [1]. Group 3: Online Business Strategy - The company is focusing on a "category king + seasonal explosive products" strategy to enhance its online business competitiveness, transitioning from quantity to quality [2]. - Key initiatives include refined operations in core business districts using AI and automation, and a marketing platform shift from manual to data-driven management [2]. Group 4: Store Transformation and Customer Experience - The company has initiated a dual-line transformation of its stores, shifting from a transactional to a relational model, aiming to transform staff into trusted health advisors to enhance customer experience [3]. - Measures to improve service quality include restructuring service philosophies, optimizing performance metrics, and enhancing training programs for frontline staff [3]. Group 5: Industry Trends and Challenges - The industry is experiencing accelerated consolidation, with a net decrease of 3,166 stores in Q1 and 4,002 stores in Q2 of 2025, leading to a total of 695,000 stores [4]. - Stricter healthcare policies are pushing for higher compliance and quality in the industry, resulting in the exit of smaller, less compliant players, while larger chains are expected to benefit from this consolidation [4]. - The company aims to capitalize on these industry changes by integrating resources through franchising and alliances to increase market share [4].

Core Viewpoint - The company held a Q3 earnings presentation on December 2, 2025, to provide insights into its performance and address investor inquiries regarding various operational aspects and market conditions [1][2]. Group 1: Earnings Presentation Overview - The earnings presentation was conducted via a video live stream and included participation from key executives, allowing for direct communication with investors [2]. - The company reported a cash dividend of 0.14 yuan per share, totaling 1.06 billion yuan distributed to shareholders [5]. Group 2: Supply and Market Conditions - The company ensured a stable supply of four categories of medicines in response to increased health demands due to a flu outbreak, with sales showing a month-on-month increase since November [3]. - The industry is experiencing accelerated consolidation, with a net decrease of 3,166 and 4,002 pharmacies in the first and second quarters of 2025, respectively, leading to a total of 695,000 pharmacies [3][4]. Group 3: Strategic Initiatives - The company is focusing on enhancing its online business, achieving a 28% year-on-year growth in online sales for the first three quarters of 2025, and plans to implement strategies for quality improvement and operational efficiency [6]. - The company has initiated a dual-line transformation in its stores, aiming to shift staff roles from sales to health advisory positions, enhancing customer experience [8]. Group 4: Financial Performance and Future Outlook - The overall gross margin decreased in the first three quarters of 2025, primarily due to an increase in the sales proportion of lower-margin products, while core business segments maintained stable or improved margins [9]. - The company is implementing measures to optimize its sales structure and improve gross margins, including refining product offerings and enhancing procurement and logistics efficiency [9].

Investment Rating - The report maintains an "Overweight" rating for the retail chain pharmacy industry [1][3]. Core Insights - The report highlights that leading pharmacies are beginning to recover from a challenging phase, with a focus on the growth potential in 2026 driven by both organic and external factors [2][3]. - The retail pharmacy market in China is projected to reach a retail scale of 611.9 billion yuan in 2024, reflecting a year-on-year decline of 1.8% due to factors such as population decrease and changes in healthcare insurance [3]. - The report identifies key companies to watch, including Yifeng Pharmacy, Dazhenglin, and Laobaixing, while also suggesting attention to Yixintang, Jianzhijia, and Shuyupingmin [3]. Summary by Sections Market Overview - The retail pharmacy market is experiencing a contraction in supply due to increased competition, with the number of physical pharmacies exceeding 700,000 in 2024, a 60% increase since 2014 [3]. - The report notes a recovery trend in the market, with a sequential growth of 6.7% in September 2025, despite a year-on-year decline of 1.9% in the first three quarters of 2025 [3]. Demand and Supply Dynamics - The demand side is showing signs of recovery, particularly in essential medicine categories, with a 6.9% sequential growth in drug retail sales in September 2025 [3]. - The report indicates that the concentration of leading pharmacy chains is expected to increase as smaller chains face operational challenges, leading to closures [3]. Future Outlook - The report anticipates that leading pharmacy chains will achieve recovery through both internal growth driven by rising flu cases and external growth via acquisitions, with a current low penetration of direct stores at about 1.5% [3][4]. - The long-term outlook remains positive for industry concentration, with expectations for continued growth in the leading pharmacy chains [3].

Core Viewpoint - The company is leveraging its nationwide supply chain and store network to meet the increasing public health demand for essential medications and protective supplies, ensuring stable supply and pricing [1] Group 1: Company Operations - The company has proactively deployed resources to secure a stable supply of four categories of medications: antiviral, antipyretic, cough relief, and antibiotics, along with masks and other protective supplies [1] - As of November, the sales of the four categories of medications have shown a month-on-month increase [1] Group 2: Market Position - The company reports that its nationwide stores have sufficient reserves of related medications and supplies, indicating a strong market position to handle increased demand [1]

证券代码：603883 证券简称：老百姓 公告编号：2025-070 老百姓大药房连锁股份有限公司关于 2025 年 第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日在上海证券交易所网站（http://www.sse.com.cn）及指定信息披露媒体披露 了《老百姓大药房连锁股份有限公司 2025 年第三季度报告》。为使广大投资者更 加全面、深入地了解公司情况，公司于 2025 年 12 月 2 日召开了 2025 年第三季 度业绩说明会，现将会议召开情况公告如下： 一、业绩说明会召开基本情况 2025 年 11 月 25 日，公司在上海证券交易所网站（http://www.sse.com.cn） 及指定信息披露媒体披露了《关于召开 2025 年第三季度业绩说明会的公告》。 2025 年 12 月 2 日 10:00-11:30，公司通过网络平台上海证券交易所上证路 演中心（http://roadshow.s ...

Summary of Conference Call on Pharmacy Sector Industry Overview - The pharmacy sector is showing signs of recovery, with positive signals from industry policies and adjustments made by pharmacies, particularly leading pharmacies like YaoXingTang, which have achieved same-store sales growth through adjustments [1][2] - The three main trends in the pharmacy industry are prescription outflow, increased industry concentration, and diversified operations [1][3] Key Points Recovery Indicators - The pharmacy sector has been consolidating at the bottom for about a year since 2024, with leading pharmacies currently at historical valuation lows [2] - Positive changes in industry policies and pharmacy operations are evident, indicating a clear upward trend [2] Major Trends 1. **Prescription Outflow**: This long-term trend significantly contributes to increased customer traffic and sales, although online prescription transfer remains slow [3] 2. **Industry Concentration**: The concentration of the top ten pharmacies in China is around 30%, compared to 80% in Japan and 70% in the US, indicating substantial room for growth [3] 3. **Diversified Operations**: Successful implementation of comprehensive adjustments by leading pharmacies in 2026 is expected to significantly boost profits [4] Company Performances - **Yifeng Pharmacy**: Designated as a "gold stock" for December, with a valuation offering good value. Same-store sales are expected to recover to over 1% growth starting Q3 2025, with projected revenue growth returning to double digits in 2026, corresponding to a PE ratio of less than 14 [5] - **Dafeng Pharmaceutical**: Achieved a profit growth of 26% in the first three quarters of 2025, with a net profit margin increasing from 3% to nearly 6%. The company plans to restart its acquisition strategy, which is expected to support future performance [6] - **Laobaixing Pharmacy**: Same-store sales turned positive starting Q3 2025, with significant contributions from acquisitions. The company is also making progress in store adjustments [7] Future Expectations - **Yifeng Pharmacy**: Expected to see improved performance in 2026, with revenue growth projected to exceed double digits and a PE ratio of less than 14, indicating a favorable investment position [5] - **Dafeng Pharmaceutical**: Anticipated to achieve over 30% net profit growth for the year, with a strong performance trend continuing into the future [6] - **Yifeng Pharmacy's Adjustments**: Plans to increase the non-pharmaceutical product ratio to 40% over the next three to five years, with significant profit contributions expected from store adjustments [7] Industry Adjustments and Projections - The pharmacy sector is expected to conduct pilot adjustments in 150 stores in 2025, with plans for comprehensive adjustments in 2026. Adjusted stores are projected to achieve a sales share of over 30%, with daily sales increasing by 1,200 yuan and gross margins improving by 18% [7] - If 70% of stores implement these adjustments, the net profit increase could exceed 500 million yuan [7] Investment Opportunities - The pharmacy sector has largely moved past policy disruptions, with ongoing improvements in same-store sales and increasing industry concentration. Leading pharmacies are now at attractive valuation levels, with growth certainty in performance [9] - Recommendations include focusing on opportunities within the pharmacy sector, particularly on stable-performing leading pharmacies like Yifeng and Dafeng [9] Data Evaluation - Data Evaluation is actively expanding and collaborating with Taiwan's Dashi Pharmacy for pilot projects in Shandong, showing optimism for future performance despite limited current data [10]

关于调整第五届董事会审计委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 12 月 1 日召开第五届董事会第十二次会议，审议通过了《关于调整第五届董事会审计委 员会成员的议案》。现将相关情况公告如下： 为进一步完善公司治理结构，推动公司规范运作，根据《中华人民共和国公 司法》《上市公司章程指引》《老百姓大药房连锁股份有限公司章程》等相关法 律、法规、规范性文件的规定，公司不再设置监事会，监事会相关职权由董事会 审计委员会承接。为更好发挥审计委员会相应职能，公司将审计委员会成员从三 名增至五名，增补武连峰先生和谭坚先生为公司第五届董事会审计委员会成员， 任期自本次董事会审议通过之日起至第五届董事会任期届满为止。具体情况如下： | 项目 | 成员 | 主任委员 | | --- | --- | --- | | 调整前 | 任明川（独立董事、会计专业人士）、李甄（非独 | 任明川 | | | 立董事）、谢子期（独立董事） | | | 调整后 | 任明川 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-068 老百姓大药房连锁股份有限公司 第五届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 具体内容详见公司在上海证券交易所网站（http://www.sse.com.cn）同日 披露的《关于调整第五届董事会审计委员会成员的公告》。 特此公告。 老百姓大药房连锁股份有限公司董事会 2025年12月1日 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日发出召开第五届董事会第十二次会议的通知，会议于 2025 年 12 月 1 日在公 司会议室以通讯方式召开，本次董事会应参加表决的董事 9 名，实际参加表决 的董事 9 名。本次会议由董事长谢子龙先生主持，董事会秘书等相关人员列席 会议。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于调整第五届董事会审计委员会成员的议案》 表决结果：同意9票，反对0票，弃权0票，表决通过。 ...

Core Viewpoint - Recent collective interest rate cuts by major banks in China are driven by various economic factors, impacting both savings and borrowing behaviors in the economy [1][3]. Group 1: Reasons for Rate Cuts - The decline in yields of wealth management products and government bonds is a significant factor, with government bond rates dropping by 0.15 percentage points in September [3]. - Increased savings willingness among residents, driven by economic uncertainties, has led to a surge in household deposits, with a notable increase of 10 trillion yuan in the first half of 2022 [3]. - The primary goal of lowering deposit rates is to alleviate pressure on the real economy, providing lower financing costs for businesses and easing mortgage burdens for homebuyers [5]. Group 2: Impacts on Daily Life - Reduced interest income from deposits is expected, exemplified by a decrease in the three-year fixed deposit rate from 2.75% to 2.60%, resulting in a loss of 1,500 yuan in interest for a 1 million yuan deposit [8]. - Lower mortgage rates, now around 4.25% compared to over 5.8% last year, will benefit homebuyers, although existing borrowers may have to wait until early next year for new rates [10]. - Inflationary pressures may persist due to increased consumer spending and lower loan rates, suggesting that demand-side inflation could remain a concern in the coming years [10].

Meeting Overview - The first temporary shareholders' meeting of the company for 2025 was held on November 28, 2025, in Changsha, Hunan Province [2] - The meeting was conducted with a combination of on-site and online voting, presided over by Chairman Xie Zilong, and complied with relevant laws and regulations [2][3] Attendance - All 8 current directors attended the meeting, while Director Liu Xiaoen submitted a resignation report on November 27, 2025, due to personal work reasons [3] - All 3 current supervisors and the board secretary attended the meeting, along with some other senior executives [3] Resolutions Passed - Several resolutions were approved, including: - Change of registered capital and amendment of the Articles of Association [4] - Revision of the Rules of Procedure for Shareholders' Meetings [4] - Revision of the Rules of Procedure for Board Meetings [5] - Revision of the Management Measures for Related Transactions [5] - Revision of the Management Measures for External Investments [5] - Revision of the Management System for Raised Funds [5] - Revision of the Management System for External Donations [5] Legal Verification - The meeting was witnessed by Hunan Qiyuan Law Firm, confirming that the meeting's procedures and voting were in compliance with legal requirements [5] Director Resignation and Election - Director Liu Xiaoen's resignation took effect upon delivery of his written report, and it will not affect the board's minimum member count or the company's operations [6][7] - On November 28, 2025, the company held a staff representative meeting to elect Tan Jian as the staff representative director, effective until the end of the current board's term [6][7] New Director Profile - Tan Jian, born in 1977, holds a bachelor's degree in Traditional Chinese Medicine and an MBA. He has been with the company since 2008 and has held various positions, including staff representative supervisor and chairman of the supervisory board [10]